HeartSciences Inc.: Form 10-Q for the period ended Oct 31, 2024
Filed with the SEC on Dec 16, 2024 and accepted by EDGAR at Dec 16, 2024, 16:03 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-10-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2024-08-01 to 2024-10-31 | $1.2m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2024-05-01 to 2024-10-31 | $2.4m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2024-08-01 to 2024-10-31 | $786.1k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2024-05-01 to 2024-10-31 | $1.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2024-08-01 to 2024-10-31 | −$2.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2024-05-01 to 2024-10-31 | −$4.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2024-08-01 to 2024-10-31 | $117.6k | us-gaap:InterestExpenseNonoperating |
| Interest expense | 6 months2024-05-01 to 2024-10-31 | $140.1k | us-gaap:InterestExpenseNonoperating |
| Net income | 3 months2024-08-01 to 2024-10-31 | −$2.1m | us-gaap:NetIncomeLoss |
| Net income | 6 months2024-05-01 to 2024-10-31 | −$4.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-08-01 to 2024-10-31 | −$2.27 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2024-05-01 to 2024-10-31 | −$4.88 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-08-01 to 2024-10-31 | −$2.27 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2024-05-01 to 2024-10-31 | −$4.88 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-08-01 to 2024-10-31 | 917,445 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2024-05-01 to 2024-10-31 | 847,990 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2024-05-01 to 2024-10-31 | −$4.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2024-05-01 to 2024-10-31 | $3.2k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-10-31 | $4.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-10-31 | $5.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-10-31 | $7.8m | us-gaap:Assets |
| Current liabilities | At period end2024-10-31 | $3.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-10-31 | $3.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-10-31 | $4.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-24-136607. Last ingested by Listed: Nov 6, 2026, 18:29 ET. Listed shows no prices and gives no investment advice.